Updated survival results of the randomized phase II study of S-1, oral leucovorin, and oxaliplatin combination therapy (SOL) versus mFOLFOX6 in patients with untreated metastatic colorectal cancer (mCRC).

被引：5
|
作者：
Otsuji, Toshio
Yamazaki, Kentaro
Ojima, Hitoshi
Kuwano, Hiroyuki
Kato, Takeshi
Shimada, Ken
Denda, Tadamichi
Esaki, Taito
Hyodo, Ichinosuke
Boku, Narikazu
机构：
[1] Dongo Hosp, Yamatotakada, Japan
[2] Shizuoka Canc Ctr, Shizuoka, Japan
[3] Gunma Prefectural Canc Ctr, Gunma, Japan
[4] Gunma Univ Hosp, Gunma, Japan
[5] Minoh City Hosp, Osaka, Japan
[6] Showa Univ, Northern Yokohama Hosp, Kanagawa, Japan
[7] Chiba Canc Ctr, Chiba, Japan
[8] Kyushu Natl Canc Ctr, Fukuoka, Japan
[9] Univ Tsukuba, Tsukuba, Ibaraki, Japan
[10] St Marianna Univ, Clin Oncol, Kanagawa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.586
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
586
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Randomized Phase II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (SOL) Versus MFOLFOX6 in Patients With Untreated Metastatic Colorectal Cancer (mCRC)
    Ojima, H.
    Yamazaki, K.
    Kuwano, H.
    Otsuji, T.
    Kato, T.
    Shimada, K.
    Denda, T.
    Esaki, T.
    Hyodo, I.
    Boku, N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S427 - S428
  • [2] A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer
    Kentaro Yamazaki
    Hiroyuki Kuwano
    Hitoshi Ojima
    Toshio Otsuji
    Takeshi Kato
    Ken Shimada
    Ichinosuke Hyodo
    Tomohiro Nishina
    Kuniaki Shirao
    Taito Esaki
    Takashi Ohishi
    Tadamichi Denda
    Masahiro Takeuchi
    Narikazu Boku
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 569 - 577
  • [3] A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer
    Yamazaki, Kentaro
    Kuwano, Hiroyuki
    Ojima, Hitoshi
    Otsuji, Toshio
    Kato, Takeshi
    Shimada, Ken
    Hyodo, Ichinosuke
    Nishina, Tomohiro
    Shirao, Kuniaki
    Esaki, Taito
    Ohishi, Takashi
    Denda, Tadamichi
    Takeuchi, Masahiro
    Boku, Narikazu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 569 - 577
  • [4] Final results of phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL plus BV; SOLA) in metastatic colorectal cancer (mCRC).
    Yamazaki, Kentaro
    Nishina, Tomohiro
    Kato, Takeshi
    Yoshino, Takayuki
    Miyata, Yoshinori
    Esaki, Taito
    Moriwaki, Toshikazu
    Boku, Narikazu
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [5] PHASE II STUDY OF S-1, ORAL LEUCOVORIN, OXALIPLATIN AND BEVACIZUMAB COMBINATION THERAPY (SOL plus BV; SOLA) IN PATIENTS WITH UNRESECTABLE METASTATIC COLORECTAL CANCER (MCRC)
    Miyata, Y.
    Nishina, T.
    Kato, T.
    Yamazaki, K.
    Yoshino, T.
    Esaki, T.
    Moriwaki, T.
    Hyodo, I.
    ANNALS OF ONCOLOGY, 2012, 23 : 131 - 131
  • [6] Phase II study of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination therapy (SOL plus BV; SOLA) in patients with unresectable metastatic colorectal cancer (mCRC).
    Kato, Takeshi
    Nishina, Tomohiro
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Miyata, Yoshinori
    Esaki, Taito
    Moriwaki, Toshikazu
    Hyodo, Ichinosuke
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [7] A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer
    Nishina, Tomohiro
    Kato, Takeshi
    Yamazaki, Kentaro
    Yoshino, Takayuki
    Miyata, Yoshinori
    Esaki, Taito
    Moriwaki, Toshikazu
    Boku, Narikazu
    Hyodo, Ichinosuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (03) : 547 - 553
  • [8] A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer
    Tomohiro Nishina
    Takeshi Kato
    Kentaro Yamazaki
    Takayuki Yoshino
    Yoshinori Miyata
    Taito Esaki
    Toshikazu Moriwaki
    Narikazu Boku
    Ichinosuke Hyodo
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 547 - 553
  • [9] Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer
    Wang, Zhi-Qiang
    Zhang, Dong-Sheng
    Xu, Nong
    Luo, De-Yun
    Deng, Yan-Hong
    Wang, Feng-Hua
    Luo, Hui-Yan
    Qiu, Miao-Zhen
    Li, Yu-Hong
    Xu, Rui-Hua
    CHINESE JOURNAL OF CANCER, 2016, 35
  • [10] Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).
    Nakamura, Masato
    Yamada, Yasuhide
    Takahari, Daisuke
    Matsumoto, Hiroshi
    Baba, Hideo
    Yoshida, Kazuhiro
    Yoshida, Motoki
    Iwamoto, Shigeyoshi
    Shimada, Ken
    Komatsu, Yoshito
    Sasaki, Yasutsuna
    Satoh, Taroh
    Takahashi, Keiichi
    Mishima, Hideyuki
    Muro, Kei
    Watanabe, Masahiko
    Sakata, Yuh
    Morita, Satoshi
    Shimada, Yasuhiro
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345